OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
RLAY
Relay Therapeutics, Inc.
There isn't enough reported data to score RLAY yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RLAY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RLAY's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RLAY PE Valuation
RLAY has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RLAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect RLAY's revenue to decline, with its earnings and profitability holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RLAY on earnings quality, reporting a profit while its opponent remains loss making.
RLAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.50 | +$0.22 |
| Q2 2026 | -$1.56 | +$0.36 |
| Q1 2026 | -$1.56 | +$0.64 |
| Q4 2025 | -$1.61 | +$0.75 |
| Q3 2025 | -$1.72 | +$0.90 |
| Q2 2025 | -$1.92 | +$0.61 |
| Q1 2025 | -$2.20 | +$0.45 |
| Q4 2024 | -$2.36 | +$0.45 |
RLAY is still losing money, but far less than before: $1.50 per share over the past year, against $3.92 at its worst in early 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RLAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RLAY on profitability, with a higher operating margin.
RLAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $350K | -48% |
| Q1 2026 | $3M | -61% |
| Q1 2025 | $7.7M | -23% |
| Q1 2024 | $10M | +4328% |
| Q3 2023 | $25.2M | +7226% |
| Q2 2023 | $119K | -67% |
| Q1 2023 | $226K | -46% |
| Q4 2022 | $253K | -99% |
RLAY's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -25950% | -14599 points |
| Q1 2026 | -2620% | -1515 points |
| Q4 2025 | -866% | N/A |
| Q2 2025 | -11351% | N/A |
| Q1 2025 | -1105% | -202 points |
| Q1 2024 | -903% | +43866 points |
| Q3 2023 | -292% | +24677 points |
| Q2 2023 | -89118% | -67800 points |
RLAY's operating margin was −25950% last quarter, down 24845 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with RLAY at down 7.9%.
RLAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$63.9M | -$1.8M |
| Q4 2025 | -$44.9M | +$13M |
| Q3 2025 | -$62.1M | +$13.2M |
| Q2 2025 | -$55.3M | +$10.6M |
| Q1 2025 | -$73.6M | -$21.5M |
| Q4 2024 | -$57.9M | +$31.4M |
| Q3 2024 | -$75.3M | +$677K |
| Q2 2024 | -$65.8M | +$4.3M |
RLAY has burned cash in almost every quarter: −$226M over the past year, against −$273M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RLAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +16.3M shares |
| 1 year | +27% | +46.8M shares |
| 3 years | +79% | +96.9M shares |
| 5 years | +136% | +126M shares |
RLAY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RLAY Net Leverage
RLAY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RLAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.9 | Neutral |
| Stochastic | 43.1 | Neutral |
RLAY's weekly RSI is 55 (neutral) and its Stochastic is 43 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RLAY PE vs Healthcare Sector
RLAY has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RLAY on trend strength, trading above more of its moving averages.
RLAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.0 | 0.6% above |
| 20 week MA | $18.7 | 3.4% below |
| 50 week MA | $14.2 | 27% above |
| 100 week MA | $9.17 | 97% above |
| 200 week MA | $9.50 | 90% above |
RLAY's trend is mixed: it's above four of its five weekly moving averages, and 90% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RLAY on returns for 2026, with the stronger performance.
RLAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.0 | $46.9 | +6.6% |
| 2021 | $46.9 | $33.4 | -29% |
| 2022 | $33.4 | $14.6 | -56% |
| 2023 | $14.6 | $11.0 | -25% |
| 2024 | $11.0 | $4.36 | -60% |
| 2025 | $4.36 | $8.56 | +96% |
| 2026 YTD | $8.56 | $18.1 | +111% |
RLAY is up 111% so far in 2026, after finishing lower in four of the previous six years.